Neuberger, E W I
Perez, I
Le Guiner, C
Moser, D
Ehlert, T
Allais, M
Moullier, P
Simon, P
Snyder, R O
Article History
Received: 14 July 2015
Revised: 2 December 2015
Accepted: 31 December 2015
First Online: 11 January 2016
Competing interests
: ROS is an inventor on patents related to rAAV technology. ROS owns equity in a gene therapy company that is commercializing adeno-associated virus for gene therapy applications. To the extent that the work reported in this article increases the value of these commercial holdings, R.O.S. has a conflict of interest.